Last reviewed · How we verify

Placebo Asenapine — Competitive Intelligence Brief

Placebo Asenapine (Placebo Asenapine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Atypical antipsychotic. Area: Psychiatry.

phase 3 Atypical antipsychotic D2 dopamine receptor, 5-HT2A serotonin receptor Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

Placebo Asenapine (Placebo Asenapine) — Organon and Co. Asenapine is an atypical antipsychotic that blocks dopamine and serotonin receptors in the brain to reduce psychotic symptoms and mood disturbances.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Placebo Asenapine TARGET Placebo Asenapine Organon and Co phase 3 Atypical antipsychotic D2 dopamine receptor, 5-HT2A serotonin receptor
Adjunctive asenapine Adjunctive asenapine Lori Davis, MD marketed Atypical antipsychotic D2 dopamine receptor, 5-HT2A serotonin receptor
Quetiapine and Topiramate Quetiapine and Topiramate University of Cincinnati marketed Atypical antipsychotic + anticonvulsant mood stabilizer combination D2 dopamine receptor, 5-HT2A serotonin receptor (quetiapine); voltage-gated sodium channels, carbonic anhydrase (topiramate)
Asenapine - Double Blind Asenapine - Double Blind Organon and Co phase 3 Atypical antipsychotic D2 dopamine receptor, 5-HT2A serotonin receptor
SAMIDORPHAN L-MALATE SAMIDORPHAN L-MALATE marketed Atypical Antipsychotic [EPC] dopamine and serotonin type 2 (5HT2) receptors, opioid receptors 2021-01-01
Lybalvi SAMIDORPHAN Alkermes Inc marketed Atypical Antipsychotic [EPC] Mu-type opioid receptor 2021-01-01
Caplyta LUMATEPERONE Intra-Cellular marketed Atypical Antipsychotic [EPC] 5-hydroxytryptamine receptor 2A 2019-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (Atypical antipsychotic class)

  1. Shanghai Mental Health Center · 10 drugs in this class
  2. AstraZeneca · 6 drugs in this class
  3. Otsuka Pharmaceutical Development & Commercialization, Inc. · 5 drugs in this class
  4. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 4 drugs in this class
  5. Eli Lilly and Company · 4 drugs in this class
  6. Otsuka Pharmaceutical Co., Ltd. · 3 drugs in this class
  7. Medical University of Vienna · 2 drugs in this class
  8. Organon and Co · 2 drugs in this class
  9. Chengdu Kanghong Pharmaceutical Group Co., Ltd. · 2 drugs in this class
  10. H. Lundbeck A/S · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo Asenapine — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-asenapine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: